Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

New pathologic scoring system could help predict survival in lung cancer patients

A new pathologic scoring system that accurately assesses how much lung tumor is left after a patient receives presurgical cancer treatments can be used to predict survival, according to new research led by investigators at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center and the Mark Foundation Center for Advanced Genomics and Imaging at the Johns Hopkins University.

6 Nov 2023

Dato-DXd improves progression-free survival in patients with metastatic non-squamous NSCLC

Treatment with datopotamab deruxtecan (Dato-DXd), a novel Trop-2 directed antibody-drug conjugate, was found to significantly improve progression-free survival in patients with metastatic non-small cell lung cancer, an improvement that was primarily driven by patients with non-squamous tumors.

26 Oct 2023

Perioperative durvalumab may change standard-of-care for patients with resectable lung cancer

A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to results of a Phase III trial reported by researchers at The University of Texas MD Anderson Cancer Center.

24 Oct 2023

Lactobacillus iners in tumors: Driving chemoradiation resistance via lactate-induced metabolic rewiring

Investigating tumor and gut microbiome traits that impact chemoradiation therapy in patients with cervical cancer.

24 Oct 2023

Perioperative immunotherapy improves event-free survival in resectable early-stage lung cancer

Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC).

22 Oct 2023

Air pollution linked to increased breast cancer risk in women

Women living and working in places with higher levels of fine particle air pollution are more likely to get breast cancer than those living and working in less polluted areas.

17 Oct 2023

New treatment options offer hope for patients with non-small cell lung cancer

More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that target molecular alterations in tumour cells, with less need for chemotherapy, following results of multiple landmark clinical trials reported for the first time in late-breaking presentations at the ESMO Congress 2023 (1-7).

17 Oct 2023

Moffitt Cancer Center researchers identify hidden target of ROS1 inhibitor lorlatinib

Targeted cancer drugs are widely used because of their ability to inhibit specific proteins involved in cancer development with fewer side effects compared to chemotherapy drugs.

16 Oct 2023

Nongenetic mechanisms play a role in lung cancer treatment resistance

In a recent study led by Ravi Salgia, M.D., Ph.D., the Arthur & Rosalie Kaplan Chair in Medical Oncology, a team of researchers from City of Hope, one of the largest cancer research and treatment organizations in the United States, and other institutions found that nongenetic mechanisms are important in lung cancer patients who develop a resistance to one cancer therapy.

13 Oct 2023

New topical drug shows promise in preventing cutaneous squamous cell carcinoma

Cutaneous squamous cell carcinoma is the second most common type of skin cancer in the United States, impacting approximately 700,000 people each year.

11 Oct 2023

Study highlights YB-1 targeting as novel treatment approach for pleural mesothelioma

Pleural mesothelioma (PM) is mainly caused by asbestos exposure and characterized by poor prognosis and limited therapeutic options.

11 Oct 2023

Liquid biopsies could be used as an early marker of immunotherapy response, study finds

Liquid biopsies are blood tests that can serially measure circulating tumor DNA (cell-free DNA that is shed into the bloodstream by dying cancer cells).

9 Oct 2023

Drug combo safely decreases pancreatic cancer growth in mice

A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.

9 Oct 2023

AI model accurately forecasts patient outcomes for common lung cancer after surgery

Researchers develop an AI model to accurately predict prognosis for patients with non-small cell lung cancer after surgery. The model, which utilized a range of preoperative and postoperative blood test results, achieved high prediction accuracy, offering a promising approach for personalized treatment plans.

25 Sep 2023

Unlocking the power of mRNA vaccines: From COVID-19 to cancer and beyond

A comprehensive review in Signal Transduction and Targeted Therapy delves into the versatility and effectiveness of mRNA vaccines, from their game-changing role in COVID-19 to potential applications in cancer and rare diseases. Despite drawbacks like stability and high immunogenicity, advancements in vaccine technology have poised mRNA platforms as a robust tool for both preventive and therapeutic interventions.

21 Sep 2023

Researchers develop new approach to fighting chemo-resistant small cell lung cancer

Small cell lung cancer accounts for about 15 percent of all diagnosed lung cancers and is still associated with a high mortality rate.

21 Sep 2023

Combination immunotherapy outperforms durvalumab monotherapy in neoadjuvant NSCLC

Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers at The University of Texas MD Anderson Cancer Center.

14 Sep 2023

New trial shows promise of combination neoadjuvant immunotherapy for lung cancer

Patients with stage 1–3 non-small cell lung cancer (NSCLC) given a combination immunotherapy prior to surgery (neoadjuvant) had a better major pathological response (10% or less residual cancer) when the cancer was removed than those who took a single immunotherapy agent alone, according to results of a novel multicenter phase 2 NeoCOAST platform trial that included two investigators from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy.

14 Sep 2023

Researchers receive £2.66M to test new immunotherapeutic strategy for non-small cell lung cancer

University of Liverpool researchers have secured £2.66m Medical Research Council funding to clinically test a novel immunotherapeutic strategy for non-small cell lung cancer – one of the most deadly cancers.

13 Sep 2023

Study reveals key reproductive factors that may increase lung cancer risk in women

A study presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer revealed that key reproductive factors such as early menopause, shortened reproductive span, and early age at first birth are associated with elevated risks of lung cancer in women.

12 Sep 2023